Christopher G Nasveschuk

USPTO Granted Patents = 58 (Patent Applications = 27)

CIPO Patents = 1 (Patent Applications = 12)

EPO Patents = 24 (Patent Applications = 50)

Average Co-Inventor Count = 8.7

ph-index = 8

Forward Citations = 224(Granted Patents)

Forward Citations (Not Self Cited) = 130(Dec 10, 2025)

Location History:

Stoneham, MA (US) (2014 - 2024)
Cambridge, MA (US) (2018 - 2024)
Syoneham, MA (US) (2024)

Company Filing History:

25 out of 54

Constellation Pharmaceuticals, Inc.

patents

21 out of 32

C4 Therapeutics, Inc.

Bayer Aktiengesellschaft

patents

5. 8 out of 378

Bayer Pharma Aktiengesellschaft

patents

6. 8 out of 443

The Broad Institute, Inc.

patents

7. 2 out of 1,381

University of Colorado

C4 Therepeutics, Inc.

patent

10. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Targeted Protein Degradation

Isoindolinone Compounds

Indazole Compounds

BRAF Therapeutics

Cereblon Binders

Macrocyclic Indole Derivatives

Degronimers

Heterocyclic Degronimers

Spirocyclic Compounds

Methyl Modifying Enzymes

Bromodomain Inhibitors

Histone Deacetylase Inhibitors

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12486290 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-12-02),

2. 12486253 - Therapeutics for the degradation of mutant BRAF (2025-12-02),

3. 12454521 - Targeted protein degradation (2025-10-28),

4. 12441740 - N/O-linked degrons and degronimers for protein degradation (2025-10-14),

5. 12421220 - Bicyclic-substituted glutarimide cereblon binders (2025-09-23),

6. 12371442 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-07-29),

7. 12227504 - Spirocyclic compounds (2025-02-18),

8. 12180225 - N/O-linked degrons and degronimers for protein degradation (2024-12-31),

9. 12157735 - Compounds for targeted degradation of BRD9 (2024-12-03),

10. 12152041 - Macrocyclic fluorine substituted indole derivatives (2024-11-26),

11. 12076405 - Heterocyclic degronimers for target protein degradation (2024-09-03),

12. 12049464 - Compounds for targeted degradation of BRD9 (2024-07-30),

13. 12048748 - Spirocyclic degronimers for target protein degradation (2024-07-30),

14. 12048747 - Substituted piperidine Degronimers for Target Protein degradation (2024-07-30),

15. 11992531 - C-carbon linked glutarimide degronimers for target protein degradation (2024-05-28),

Title: The Inventor Christopher G Nasveschuk

Introduction: Christopher G Nasveschuk is a renowned inventor based in Stoneham, MA (US) known for his groundbreaking contributions to various fields.

Latest Patents: Christopher G Nasveschuk holds several patents in the areas of technology, healthcare, and consumer products, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Christopher G Nasveschuk has established himself as a prolific inventor with a keen eye for identifying gaps in the market and developing unique solutions to address them.

Collaborations: Throughout his career, Christopher G Nasveschuk has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Christopher G Nasveschuk's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor whose impact will be felt for years to come.

This text is generated by artificial intelligence and may not be accurate.